Search hospitals > Missouri > Kansas City

Research Medical Center

Claim this profile
Kansas City, Missouri 64132
Global Leader in Parotid Gland Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Adult T-Cell Leukemia/Lymphoma
Conducts research for Relapse
296 reported clinical trials
7 medical researchers
Photo of Research Medical Center in Kansas CityPhoto of Research Medical Center in Kansas CityPhoto of Research Medical Center in Kansas City

Summary

Research Medical Center is a medical facility located in Kansas City, Missouri. This center is recognized for care of Parotid Gland Cancer, Breast Cancer, Lung Cancer, Adult T-Cell Leukemia/Lymphoma, Relapse and other specialties. Research Medical Center is involved with conducting 296 clinical trials across 425 conditions. There are 7 research doctors associated with this hospital, such as Dhanunjaya Lakkireddy, Suman Kambhampati, Rakesh Gaur, and Naga Venkata K. Pothineni, MD.

Area of expertise

1Parotid Gland Cancer
Global Leader
Research Medical Center has run 62 trials for Parotid Gland Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Breast Cancer
Global Leader
Research Medical Center has run 51 trials for Breast Cancer. Some of their research focus areas include:
HER2 negative
Stage IV
ER positive

Top PIs

Clinical Trials running at Research Medical Center

Breast Cancer
Breast cancer
Lung Cancer
Cancer
Small Cell Lung Cancer
Multiple Myeloma
Cardiotoxicity
Adult T-Cell Leukemia/Lymphoma
Lymphoid Hematopoietic Disease
Parotid Gland Cancer
Image of trial facility.

Carvedilol

for Preventing Heart Problems in HER2 Positive Breast Cancer

This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Recruiting2 awards Phase 323 criteria
Image of trial facility.

Pembrolizumab

for Triple-Negative Breast Cancer

The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Image of trial facility.

Marker-Directed Monitoring

for Breast Cancer

This trial studies if using blood tests to decide when to do scans is as effective as the standard way for monitoring patients with a specific type of breast cancer that has spread. The blood tests act like an early warning system for cancer activity.
Recruiting1 award N/A

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Research Medical Center?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security